PDFファイル
Contents
1. EN a PAN PAN POD I0G H 0G2. 8 P N
3. 3 IgG 3 lo6 3 4 150mlU mL 0 100 0 200AA 734 99 696 IgG 46 10096 IgG 3 Am CV Am CV A 82 11 4 50 21 6 B 589 4 4 C 1403 5 8 1469 6 4 5
4. 5 37 1 60 2 6 03mL 4 7 100uL 8 37 1 60 2 9 a
5. E 18 25C 30 2 100uL 0 1 450nm 650nm 615 H BEP BEP T BEP BEP PAN 1 20 371C 1 20
6. 56C 30 1 18 25C 18 25C 1 POD gG 1 50 ho
7. 3 al HIV HBV HCV 121C 1 2
8. SSEP 7 2 tr0 Diagnostic Directive in the EU FDA CInVi H PN EU HBs HCV HIV1 HIV2 Il
9. 2 8C 1 12 2 12 P N 18 18 POD gG 18 36 24 24 22 60 96 1 2 McLean AR Anderson RM Measles in developing COuntries Epidemiol Infect 1988 100 111 33 Bloch AB Orenstein WA Stetler HC et al Health impact of measles vaccination in he United States Pediatrics 1985 76 524 32 Weigle KA Murphy MD Brunell PA Enzyme linked immunosorbent assay for evaluation of Immunity to measles virus J Clin Microbiol 1984 19 376 9 Cremer NE Cossen CK Shell G et al EnZyme Immun0aSSay versus plaque neutralization and other methods for determination of immune status to measles and Varicella Z0Ster viruses and versus complement fixation for serodiagnosis of infections with those viruses J Clin Microbiol 1985 21 869 74 Hull HF Montes JM Hays PC Lucer
10. BEP 37 1C 450nm 650nm 615 690nm 4 1 PAN PAN 1 20 20uL 400uL 2 8C 2 2 P N 2
11. 250uL POD lMG 1 12 5mL 1 25mL 0mL 20 nl 1 1mL 10mL 1
12. PAN 2096 BEP invalid test result 2 BEP BEP P N P N AA P N AA P
13. 0 1 20 2 8C PAN 2 8C 8 2 8C 2 8C 2 8C 5 i 9 2 2 8C 1 19 2 8C 1 a 18 25C 1 2 8C 690nm 2 8C BEP BEP 3 1 4 ELISA I BEP
14. L o 400 2 8C 5 2 8C A sty p 8 POD G 2 8C 12 ie G 50 2 8C 4 5 1 2 8C 8 PA 2 8C 12 100uL
15. E 3 1 230 1 lg9G g E 3 2 PIN 01 E 0 5 IgG IgG
16. POD 6 Bm 367 H el 6
17. WHO 1st IS 1 HV HBV HCV 3 F HIV 39 mg lQM gM lgG 0
18. mlU mL 1 2 8C 3 18 25C ho A H H AAMA I9G IgM HBs M loM EBVIoM CMV lgM E 8
19. AA 1 2 2309 omlU mL a x AA o CInterna 0 10 H E 25 1 2309 231 10 al Reference Preparation WHO 1964 9 a 2 gt
20. Anti Measles Virus lgG Test plate 2 Sample Buffer POD 3 P N Anti Measles Virus Reference P N 4 POD lgG 50mLX2 0 4mLX1 1mLX1 96 X2 Anti Human IgG POD Conjugate POD IgG 5 12 5mL X 4 Conjugate Buffer Microbiol 6 1 1 1 8 1 3mLX 4 Chromogen TMB 2 30mLX4 Buffer Substrate TMB 3 100mL Xx 3 Washing Solution POD 4 100mL
21. 3 200uL P N 1 A1 A2 1 1 20 P N 20uL 20uL P N 20uL PAN 2 1 15 8
22. IgG lgG IgG 1 H
23. N AA AA 0 100 AA gt 0 200 0 10 0 AA 0 200 BI AA E E IgG O EAA lt E A 2 5 f C Log
24. X 2 Stopping Solution POD 5 24 1 12 5mLX1 Color Solution blue for Enzygnost lgG 9G POD loG IgG lg6
25. 0uL PAN 20uL 20uL PAN 20uL 60 2 4 100L 4 100uL 18 25C 30 2 100uL 1 450nm 650nm BEP AA 3 a E 1 PIN AA AA Reference P N AA
26. OWLN SIEMENS 2013 4 2 2008 10 1 20500AMYO0025000 G IgG Enzygnost8 Anti Measles Virus IgG M 1 1
27. o RL Risk factors for measles vaccine failure among ImmuniZed students Pedialrics 1985 76 518 23 Gustafson TL Lievens AW Brunell PA et al Measles outbreak in a fully ImmuniZed secondarV school population N Engl J Med 1987 26 316 771 4 Eghafona NO 0dama LE Emejuaiwe S0 et al Measles antibody levels in children of rural and urban areas of Nigeria following vaccination Campaidn WHO Expert Committee on Biological Standardization Seventeenth Report Geneva World Healh Organization Tech Rep Ser 1964 293 18 9 Krasinski K Borkowsky W Measles and measles immunity in children infected with human Immun0deficiency virus JAMA 1989 261 2512 6 10 Jenks PJ Caul E0 Roome AP Maternally derived measles Immunity In children of naturally Infected and vaccinated mothers Epidemiol Infect 1988 101 473 6 TEL 03 3493 8400 1 11 1 F DL 114 013D 0WLNG 15C 0503
Download Pdf Manuals
Related Search